261 related articles for article (PubMed ID: 28301689)
1. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Schroeck FR; Bekelman JE; Kahn JM; Nelson JB; Barnato AE
Cancer; 2017 Aug; 123(15):2945-2954. PubMed ID: 28301689
[TBL] [Abstract][Full Text] [Related]
2. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
Yu JB; Cramer LD; Herrin J; Soulos PR; Potosky AL; Gross CP
J Clin Oncol; 2014 Apr; 32(12):1195-201. PubMed ID: 24616315
[TBL] [Abstract][Full Text] [Related]
4. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD
J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693
[TBL] [Abstract][Full Text] [Related]
5. Stereotactic Body Radiation Therapy, Intensity-Modulated Radiation Therapy, and Brachytherapy Boost Modalities in Invasive Cervical Cancer: A Study of the National Cancer Data Base.
OʼDonnell B; Shiao JC; Pezzi TA; Waheed N; Sharma S; Bonnen MD; Ludwig MS
Int J Gynecol Cancer; 2018 Mar; 28(3):563-574. PubMed ID: 29324547
[TBL] [Abstract][Full Text] [Related]
6. Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy.
Liu BY; Rehmani S; Kale MS; Marshall D; Rosenzweig KE; Kong CY; Wisnivesky J; Sigel K
Chest; 2022 Jun; 161(6):1666-1674. PubMed ID: 35063448
[TBL] [Abstract][Full Text] [Related]
7. Changing trends in radiation therapy technologies in the last year of life for patients diagnosed with metastatic cancer in the United States.
Guadagnolo BA; Huo J; Liao KP; Buchholz TA; Das P
Cancer; 2013 Mar; 119(5):1089-97. PubMed ID: 23132206
[TBL] [Abstract][Full Text] [Related]
8. Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016.
Mukherjee K; Small W; Duszak R
Brachytherapy; 2022; 21(1):12-21. PubMed ID: 34380592
[TBL] [Abstract][Full Text] [Related]
9. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity.
Yu JB; Soulos PR; Herrin J; Cramer LD; Potosky AL; Roberts KB; Gross CP
J Natl Cancer Inst; 2013 Jan; 105(1):25-32. PubMed ID: 23243199
[TBL] [Abstract][Full Text] [Related]
10. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
[TBL] [Abstract][Full Text] [Related]
11. The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications.
Roberts KB; Soulos PR; Herrin J; Yu JB; Long JB; Dostaler E; Gross CP
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1186-92. PubMed ID: 23182396
[TBL] [Abstract][Full Text] [Related]
12. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
[TBL] [Abstract][Full Text] [Related]
13. Local coverage determination policy and the use of stereotactic body radiation therapy for prostate cancer.
Jacobs BL; Sunderland R; Yabes J; Nelson JB; Barnato AE; Bekelman JE
Urol Pract; 2015 Nov; 2(6):304-311. PubMed ID: 27493987
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
[TBL] [Abstract][Full Text] [Related]
15. [Stereotactic body radiation therapy versus conventional intensity-modulated radiation therapy for the treatment of prostate cancer].
Gao QN
Zhonghua Nan Ke Xue; 2019 May; 25(5):424-429. PubMed ID: 32216228
[TBL] [Abstract][Full Text] [Related]
16. Influence of Geography on Prostate Cancer Treatment.
Tang C; Lei X; Smith GL; Pan HY; Hoffman KE; Kumar R; Chapin BF; Shih YT; Frank SJ; Smith BD
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1286-1295. PubMed ID: 33316361
[TBL] [Abstract][Full Text] [Related]
17. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer.
Sheets NC; Goldin GH; Meyer AM; Wu Y; Chang Y; Stürmer T; Holmes JA; Reeve BB; Godley PA; Carpenter WR; Chen RC
JAMA; 2012 Apr; 307(15):1611-20. PubMed ID: 22511689
[TBL] [Abstract][Full Text] [Related]
18. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
Dee EC; Muralidhar V; King MT; Martin NE; D'Amico AV; Mouw KW; Orio PF; Nguyen PL; Leeman JE
Radiother Oncol; 2021 Aug; 161():241-250. PubMed ID: 34171451
[TBL] [Abstract][Full Text] [Related]
19. Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm.
Tran JH; Mhango G; Park HS; Marshall DC; Rosenzweig KE; Wang Q; Wisnivesky JP; Veluswamy RR
Clin Lung Cancer; 2023 Jan; 24(1):e9-e18. PubMed ID: 36443153
[TBL] [Abstract][Full Text] [Related]
20. National variation in the delivery of radiation oncology procedures in the non-facility-based setting.
Valle LF; Chu FI; Kundu P; Yoon SM; Gilchrist T; Steinberg ML; Raldow AC
Cancer Med; 2021 Jul; 10(14):4734-4742. PubMed ID: 34076341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
